Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

KTRA
Kintara Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive
Oct 17, 2024
7.54USD-6.307%(-0.51)105,721
Pre-market
0.00USD-100.000%(-8.05)0
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
07:28AM EST  10 Biggest Price Target Changes For Thursday   Benzinga
05:38AM EST  HC Wainwright & Co. Maintains Buy on Kintara Therapeutics, Lowers Price Target to $3   Benzinga
Jan 12, 2022
08:03AM EST  Kintara Announces Grant From Luxembourg National Research Fund And Cancer Foundation Luxembourg To Support VAL-083's Mechanism Of Action Research In Glioblastoma   Benzinga
08:01AM EST  Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma   PR Newswire
Jan 5, 2022
08:03AM EST  Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2022 Virtual   PR Newswire
Dec 7, 2021
08:03AM EST  Kintara Therapeutics to Present at the MedInvest Oncology Investor Conference   PR Newswire
Nov 30, 2021
04:47PM EST  Kintara Announces First International Site Activation In GCAR Phase 2/3 Clinical Trial For Glioblastoma   Benzinga
08:01AM EST  Kintara Announces First International Site Activation in GCAR Phase 2/3   PR Newswire
Nov 18, 2021
08:10AM EST  Kintara Presents Updates On Two Phase 2 Clinical Studies On Neuro-oncology   RTTNews
08:09AM EST  Kintara Therapeutics Highlights Presentation Of Updates On 2 Phase 2 Studies At 'Society For Neuro-Oncology' Meeting Nov. 18-21   Benzinga
08:03AM EST  Kintara Presents Updates on Two Phase 2 Clinical Studies at the 2021 Society   PR Newswire
Nov 15, 2021
11:07AM EST  Kintara Therapeutics Q1 EPS $(0.25) Up From $(0.36) YoY   Benzinga
08:15AM EST  Kintara Therapeutics Announces Fiscal 2022 First Quarter Financial Results and   PR Newswire
Nov 11, 2021
08:31AM EST  Kintara Therapeutics to Present at the Q4 Investor Summit Virtual Conference on   PR Newswire
Nov 9, 2021
11:45AM EST  Kintara Appoints Robert E. Hoffman President And CEO   Benzinga
08:03AM EST  Kintara Announces Changes to Executive Leadership Team   PR Newswire
Oct 19, 2021
05:15AM EDT  KTRA: FY21 Financial Results   Benzinga
Oct 13, 2021
06:43AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.15 A.M. EDT).   RTTNews
Oct 11, 2021
08:02AM EDT  Kintara Therapeutics to Present at the LD Micro Main Event Conference   PR Newswire
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 2, 2021
05:34AM EDT  KTRA: 2Q:21 Update   Benzinga
Sep 30, 2021
09:45AM EDT  Aegis Capital Maintains Buy on Kintara Therapeutics, Lowers Price Target to $5   Benzinga
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
07:16AM EDT  Kintara Therapeutics: Q4 Earnings Insights   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
08:13AM EDT  Kintara Therapeutics FY21 EPS $(1.60), Down From $(0.87) YoY   Benzinga
08:11AM EDT  Kintara Therapeutics FY Loss Per Share $1.60 Vs Loss $0.87 Last Year   RTTNews
08:02AM EDT  Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides   PR Newswire
Sep 28, 2021
01:34PM EDT  Kintara Announces Closing of $15.0 million Offering Priced at a Premium to   PR Newswire
10:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2021   Benzinga
06:20AM EDT  HC Wainwright & Co. Initiates Coverage On Kintara Therapeutics with Buy Rating, Announces Price Target of $6   Benzinga
Sep 24, 2021
08:02AM EDT  Kintara Announces $15M Offering Of Common Stock And Warrants Priced At A Premium To Market   Benzinga
08:01AM EDT  Kintara Announces $15.0 million Offering of Common Stock and Warrants Priced at   PR Newswire
Sep 22, 2021
08:19AM EDT  Kintara: Topline Results From Adjuvant Arm Affirms   RTTNews
08:05AM EDT  Kintara Reports Positive Results From Phase 2 Study Of VAL-083 As Adjuvant Therapy For Newly-Diagnosed GBM Patients   RTTNews
08:02AM EDT  Kintara Therapeutics Reports Topline Results From Phase 2 Study Of VAL-083 As Adjuvant Therapy For Newly-Diagnosed Glioblastoma Multiforme Patients   Benzinga
08:01AM EDT  Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as   PR Newswire
Aug 17, 2021
08:05AM EDT  Kintara Therapeutics Announces VAL-083 Treatment Arm In Global Coalition For Adaptive Research Registrational Phase 2/3 Trial For Glioblastoma Has Been Activated In 26 US Sites As Of Aug. 16   Benzinga
08:01AM EDT  Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3   PR Newswire
Aug 12, 2021
08:02AM EDT  Kintara Therapeutics to Present at the Investor Summit Virtual Conference on   PR Newswire
Aug 4, 2021
08:02AM EDT  Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on   PR Newswire
Jul 14, 2021
06:31AM EDT  KTRA: Phase II Topline   Benzinga
Jul 9, 2021
10:47AM EDT  Kintara Therapeutics Shares See Volume; Zacks SCR Issues Report On Co's Phase 2 Topline Results   Benzinga
Jul 1, 2021
01:37PM EDT  Kintara Therapeutics Shows Encouraging Safety, Efficacy Data From Brain Cancer Study With VAL-083   Benzinga
01:37PM EDT  Kintara Therapeutics Shares Move Higher On Encouraging Safety, Efficacy Data From Brain Cancer Study With VAL-083   Benzinga
08:30AM EDT  Kintara Therapeutics Inc. (KTRA) revealed a promising results from phase 2 clinical trial of VAL-083 for recurrent glioblastoma multiforme. The results provided important safety and efficacy data to support further evaluation of VAL-083 for the treatment of glioblastoma multiforme or GBM.   RTTNews
08:02AM EDT  Kintara Reports Topline Results From Phase 2 Clinical Trial Of VAL-083 For Recurrent GBM; Median Overall Survival Is 8 Months   Benzinga
08:01AM EDT  Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for   PR Newswire
Jun 7, 2021
08:15AM EDT  Kintara Therapeutics To Join Russell Microcap Index   Benzinga
08:02AM EDT  Kintara Therapeutics Set to Join Russell Microcap(r) Index   PR Newswire
Jun 3, 2021
08:03AM EDT  Kintara Therapeutics Says Enrolls Final Patient In Phase 2 Trial Of VAL-083 For Adjuvant Treatment Of Brain Tumors   RTTNews
08:02AM EDT  Kintara Therapeutics Enrolls Final Patient In Phase 2 Clinical Trial Of VAL-083 For Adjuvant Treatment Of Brain Tumors   Benzinga
08:01AM EDT  Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083   PR Newswire
Jun 2, 2021
08:01AM EDT  Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference   PR Newswire
May 26, 2021
12:25PM EDT  Kintara Stock Soars After Site Activation Update On Glioblastoma Trial   Benzinga
08:15AM EDT  Kintara Therapeutics Provides Positive Site Activation Update On GCAR Phase 2/3 Clinical Trial For Glioblastoma   RTTNews
08:04AM EDT  Kintara Therapeutics Announces VAL-083 Treatment Arm In Global Coalition For Adaptive Research Registration Of Phase 2/3 Trial For Glioblastoma Multiforme Has Been Activated In 15 US Sites   Benzinga
08:02AM EDT  Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3   PR Newswire
May 14, 2021
08:54AM EDT  Kintara Therapeutics Q3 EPS $(0.23) Down From $(0.17) YoY   Benzinga
08:40AM EDT  Amended: Kintara Therapeutics Q3 Loss Per Share $0.23 Vs Loss Per Share $0.17 Last Year   RTTNews
08:36AM EDT  Kintara Therapeutics Q1 Loss Per Share $0.23 Vs Loss Per Share $0.17 Last Year   RTTNews
08:01AM EDT  Kintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and   PR Newswire
06:48AM EDT  Schedule For Benzinga's Global Small Cap Conference Friday, May 14, 2021   Benzinga
06:26AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Friday, May 14, 2021 (BZ Small Cap Event Edition): EQOS, KTRA, AMST, SPCB, SYTA   Benzinga
May 5, 2021
08:02AM EDT  Kintara Therapeutics to Participate at the Benzinga Global Small Cap Conference   PR Newswire
May 4, 2021
08:28AM EDT  Kintara Therapeutics Appoints Tamara Seymour To Board   RTTNews
08:02AM EDT  Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors   PR Newswire
Apr 12, 2021
08:24AM EDT  Kintara Presents Interim Data Results On Two Phase 2 Clinical Trials Of VAL-083 At AACR Annual Meeting   RTTNews
08:03AM EDT  Kintara Highlights Updates On Two Phase 2 Clinical Trials Of VAL-083 At 2021 American Association For Cancer Research Annual Meeting   Benzinga
08:01AM EDT  Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American   PR Newswire
Apr 5, 2021
10:52AM EDT  Kintara Taking The Lead In Developing New And Innovative Rare Cancer Therapies   Benzinga
Mar 25, 2021
02:45PM EDT  Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference   Benzinga
Mar 23, 2021
07:12PM EDT  Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021   Benzinga
Mar 17, 2021
08:02AM EDT  Kintara Therapeutics to Participate in Benzinga Biotech Small Cap Conference   PR Newswire
Mar 10, 2021
08:02AM EST  Kintara Therapeutics to Participate in Maxim Group's 2021 Emerging Growth   PR Newswire
Mar 3, 2021
08:01AM EST  Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board   PR Newswire
Mar 2, 2021
08:02AM EST  Kintara Therapeutics to Present at the H.C. Wainwright Global Life Sciences   PR Newswire
Feb 17, 2021
12:56PM EST  Kintara Therapeutics Concludes Enrollment In Recurrent Arm Of VAL-083 Mid-Stage Brain Cancer Study   Benzinga
08:25AM EST  Kintara Therapeutics Enrolls Final Patient In Phase 2 Clinical Trial Of VAL-083 For Recurrent GBM   RTTNews
08:02AM EST  Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083   PR Newswire
08:01AM EST  Kintara Therapeutics Reports Enrollment Of Final Patient In Phase 2 Trial Of VAL-083 For Recurrent Glioblastoma Multiforme   Benzinga
Feb 12, 2021
08:32AM EST  Kintara Therapeutics Q2 EPS $(0.22), Down From $(0.15) YoY   Benzinga
08:30AM EST  Kintara Therapeutics Announces Fiscal Second Quarter 2021 Financial Results and   PR Newswire
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Feb 3, 2021
11:32AM EST  Aegis Capital Maintains Buy on Kintara Therapeutics, Raises Price Target to $7   Benzinga
Jan 27, 2021
07:36AM EST  The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement   Benzinga
Jan 26, 2021
08:07AM EST  The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market   Benzinga
Jan 13, 2021
08:15AM EST  Kintara Initiates Patient Recruitment For VAL-083's Study Arm In GBM AGILE Trial   RTTNews
08:13AM EST  Kintara Announces Initiation Of Patient Recruitment For VAL-083's Study Arm In GBM AGILE Trial   Benzinga
08:02AM EST  Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in   PR Newswire
Jan 6, 2021
01:07PM EST  Kazia Therapeutics Shares Move Higher On Volume Following Press Release From Global Coalition For Adaptive Research Highlighting News GCAR, Kazia, Kintara Began Kazia's Paxalisib, Kintara's VAL-083 In Glioblastoma Adaptive Global Innovative Learning Envir   Benzinga
Jan 5, 2021
08:01AM EST  Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual   PR Newswire
Dec 3, 2020
08:31AM EST  Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development   PR Newswire
Nov 19, 2020
08:17AM EST  The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway   Benzinga
08:06AM EST  Kintara Therapeutics Reports 10 Months Progression-Free Survival In Newly-Diagnosed MGMT-Unmethylated GBM From Ongoing MD Anderson Cancer Center Phase 2 Study   Benzinga
08:01AM EST  Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study   PR Newswire
05:53AM EST  What's moving these stocks in the pre-market hours today?   RTTNews
Nov 13, 2020
08:08AM EST  Kintara Therapeutics Q1 EPS $(1.33) Down From $(0.21) YoY   Benzinga
08:07AM EST  Kintara Therapeutics Q1 Net Loss $19.5 Mln Or $1.33/shr Vs. Net Loss Of $1.6 Mln Or $0.21/shr Prior Year   RTTNews
08:00AM EST  Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and   PR Newswire
Oct 21, 2020
08:22AM EDT  Kintara,e Global Coalition For Adaptive Research Execute Agreement For VAL-083's Participation In GBM AGILE Study   RTTNews
08:04AM EDT  Kintara And The Global Coalition For Adaptive Research Execute Agreement For VAL-083's Participation In The GBM AGILE Registrational Study   Benzinga
08:02AM EDT  Kintara and the Global Coalition for Adaptive Research Execute Agreement for   PR Newswire
Sep 24, 2020
06:18PM EDT  KTRA: Two Phase III Ready Assets   Benzinga
Sep 21, 2020
08:39AM EDT  Kintara Therapeutics FY20 EPS $(0.87) Up From $(3.16) YoY, Had Cash And Equivalents ~$2.4M At Jun. 30   Benzinga
08:31AM EDT  Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent   PR Newswire
Sep 14, 2020
03:32PM EDT  Why Kintara's Stock Is Trading Higher Today   Benzinga
10:50AM EDT  Aegis Capital Initiates Coverage On Kintara Therapeutics with Buy Rating, Announces Price Target of $6   Benzinga
Sep 1, 2020
08:33AM EDT  Kintara Therapeutics Completes Final Closing Of Previously Announced Private Placement For $25 Mln   RTTNews
08:31AM EDT  Kintara Therapeutics Completes Final Closing of Previously Announced Private   PR Newswire
Aug 26, 2020
08:31AM EDT  Kintara Therapeutics (formerly DelMar Pharmaceuticals) to Present at the LD   PR Newswire
Aug 25, 2020
08:34AM EDT  Kintara Therapeutics Announces Closing Of Addl $2.2 Mln Private Placement Priced At The Market   RTTNews
08:31AM EDT  Kintara Therapeutics Announces Closing of Additional $2.2 Million Private   PR Newswire
Aug 21, 2020
08:16AM EDT  Kintara Therapeutics Announces Additional $2.4 Million Private Placement Priced   PR Newswire
08:03AM EDT  Kintara Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Requirement; BZ NOTE: Co Was Formerly DelMar Pharmaceuticals   Benzinga
08:03AM EDT  Kintara Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Requirement   RTTNews
08:01AM EDT  Kintara Therapeutics (formerly DelMar Pharmaceuticals) Regains Compliance with   PR Newswire
Aug 20, 2020
08:41AM EDT  Kintara Therapeutics Announces Completion Of Merger With Adgero Biopharmaceuticals; Closing Of $19.6M Private Placement Priced At-The-Market   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC